Stress Hyperglycemia. Potential Role of Incretin Analogs

June 7, 2010 updated by: Hospital Universitari Son Dureta

Stress Hyperglycemia in Critically Ill Patients. Potential Role of Incretin Analogs. A Preliminary Study

This is a prospective observational study to examine the levels of glucoregulatory hormones, with special focus on incretins levels, in critically ill patients with stress hyperglycemia.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Illes Balears
      • Palma de Mallorca, Illes Balears, Spain, 07014
        • Hospital Universitari Son Dureta. Intensive Care Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Medical-surgical ICU patients

Description

Inclusion Criteria:

  • Age > 18 years
  • Emergent ICU admission
  • Written informed consent from patient or relative.

Exclusion Criteria:

  • Previously known type I or type II diabetes.
  • Patients who received insulin or oral antidiabetic agents before ICU admission.
  • Malignancies.
  • Scheduled surgery
  • Patients receiving enteral or parenteral nutrition.
  • Inability to obtain informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incretins plasmatic levels
Time Frame: 28 days
28 days and ICU mortality
28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
glucagon
Time Frame: 28 days
28 days and ICU mortality
28 days
insulin
Time Frame: 28 days
28 days and ICU mortality
28 days
cortisol
Time Frame: 28 days
28 days and ICU mortality
28 days
HOMA index
Time Frame: 28 days
28 days and ICU mortality
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Universitari Son Dureta

Collaborators

Fundació Mateu Orfila

Investigators

  • Principal Investigator: Juan A Llompart-Pou, M.D., Hospital Universitari Son Dureta. Intensive Care Unit

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

April 1, 2010

Study Completion (Actual)

April 1, 2010

Study Registration Dates

First Submitted

March 11, 2010

First Submitted That Met QC Criteria

March 15, 2010

First Posted (Estimate)

March 16, 2010

Study Record Updates

Last Update Posted (Estimate)

June 8, 2010

Last Update Submitted That Met QC Criteria

June 7, 2010

Last Verified

June 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Incretins2010

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperglycemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe